An intervention to reduce unhealthy alcohol use for people living with HIV in Vietnam

IGHID 12230 - Scaling up the Brief Alcohol Intervention to Prevent HIV Infection in Vietnam: a Cluster Randomized, Implementation Trial (EBAI)

Not applicable Interventional University of North Carolina, Chapel Hill · NCT06358885

This study tests two different ways to help people living with HIV in Vietnam cut down on unhealthy drinking and see if it helps them manage their health better.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment930 (estimated)
Ages18 Years and up
SexAll
SponsorUniversity of North Carolina, Chapel Hill Academic / other
Locations1 site (Hanoi)
Trial IDNCT06358885 on ClinicalTrials.gov

What this trial studies

This implementation trial evaluates two strategies to scale up a Brief Alcohol Intervention (BAI) in ART clinics in Vietnam. One group will receive facilitation support to overcome barriers to BAI implementation, while the other group will also participate in an experiential learning component to address their own alcohol-related behaviors. The trial involves 30 ART clinics and aims to assess both implementation and effectiveness outcomes, particularly focusing on viral suppression among participants. The study employs a cluster-randomized design to compare the two approaches.

Who should consider this trial

Good fit: Ideal candidates include individuals living with HIV who are currently attending ART clinics and exhibit unhealthy alcohol use.

Not a fit: Patients with psychological disturbances or cognitive impairments that prevent participation may not benefit from this study.

Why it matters

Potential benefit: If successful, this intervention could significantly improve alcohol use outcomes and viral suppression in people living with HIV.

How similar studies have performed: Other studies have shown success with similar alcohol intervention approaches, indicating potential for positive outcomes in this context.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

PWH cohort participants

* Person living with HIV at any stage of HIV infection
* Currently attending the study ART clinic at any ART stage (initiating or receiving ART)
* AUDIT-C score \>=4 for men or \>=3 for women
* \>= 18 years of age
* Willing to provide informed consent, which includes consenting to interview and collection of dried blood spots

Clinic staff participants:

* Work at the ART clinic as a clinic director, physician, nurse, or counselor
* Willing to provide informed consent

Exclusion Criteria:

PWH cohort participants:

* Psychological disturbance preventing participation
* Cognitive impairment
* Threatening behavior
* Unwilling to provide locator information Note: If a participant screens positive with the AUDIT-C and is identified to be at substantial risk for alcohol withdrawal based on the Mini International Neuropsychiatric Interview (MINI) and Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA) will be referred for treatment. They will not be eligible for enrollment until after alcohol withdrawal concerns are addressed.
* These participants may be rescreened, consented, and enrolled after treatment.

Clinic staff participants:

* Psychological disturbance, cognitive impairment, or threatening behavior

Where this trial is running

Hanoi

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions HIV-1-infectionUnhealthy Alcohol UseAlcohol interventionCluster randomized controlled implementation trialImplementation ScienceHIV/AIDSAntiretroviral therapyCognitive behavioral therapy
Last reviewed 2026-06-10 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.